Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000674902 | SCV000800313 | likely pathogenic | DE SANCTIS-CACCHIONE SYNDROME; Cerebrooculofacioskeletal syndrome 1; Cockayne syndrome type 2 | 2018-05-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001061726 | SCV001226479 | pathogenic | not provided | 2022-12-11 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 225905). This premature translational stop signal has been observed in individual(s) with Cockayne syndrome (PMID: 27186691). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Glu215*) in the ERCC6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ERCC6 are known to be pathogenic (PMID: 18628313, 29572252). |
Fulgent Genetics, |
RCV005044434 | SCV005681657 | pathogenic | DE SANCTIS-CACCHIONE SYNDROME; Cerebrooculofacioskeletal syndrome 1; Cockayne syndrome type 2; UV-sensitive syndrome 1; Age related macular degeneration 5; Premature ovarian failure 11; Lung cancer | 2024-06-12 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000211122 | SCV000268077 | pathogenic | Premature ovarian failure 11 | 2020-05-27 | no assertion criteria provided | literature only |